Structure-function of the tumor suppressor BRCA1

Computational and Structural Biotechnology Journal

Volumn 1, Issue 1, 2012, Pages e201204005-

  Clark, Serena L ^a   Rodriguez, Ana M ^a   Snyder, Russell R ^a   Hankins, Gary D V ^a   Boehning, Darren ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888854732     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.5936/csbj.201204005     Document Type: Short Survey

References (71)

1. ACOG Committee on Practice Bulletins (2009) Hereditary breast and ovarian cancer syndrome. Gynecol Oncol 113:6-11.
2. Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12:68-78.
3. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, et al. (1999) Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 4:1093-1099. (Pubitemid 30054915)
4. Scully R, Livingston DM (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408:429-432.
5. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689. (Pubitemid 120031871)
6. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, et al. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2-13. Science 265:2088-2090. (Pubitemid 24325690)
7. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, et al. (2010) The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 7:708-717.
8. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. lama 306:1557-1565.
9. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, et al. (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413-1416. (Pubitemid 26382501)
10. Johannsson OT, Ranstam J, Borg A, Olsson H (1998) Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16:397-404. (Pubitemid 28135579)
11. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, et al. (2011) Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 22:1346-1352.
12. Irwin JJ (2008) Community benchmarks for virtual screening. J Comput Aided Mol Des 22:193-199.
13. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE (2001) Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 8:833-837. (Pubitemid 32923599)
14. Williams RS, Green R, Glover JN (2001) Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8:838-842. (Pubitemid 32923600)
15. Williams RS, Lee MS, Hau DD, Glover JN (2004) Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 11:519-525. (Pubitemid 38691918)
16. Varma AK, Brown RS, Birrane G, Ladias JA (2005) Structural basis for cell cycle checkpoint control by the BRCAl-CtIP complex. Biochemistry 44:10941-10946. (Pubitemid 41209030)
17. Gaiser OJ, Ball LJ, Schmieder P, Leitner D, Strauss H, et al. (2004) Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1. Biochemistry 43:15983-15995. (Pubitemid 40041012)
18. Shiozaki EN, Gu L, Yan N, Shi Y (2004) Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell 14:405-412. (Pubitemid 38591411)
19. Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, et al. (2004) Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 11:512-518. (Pubitemid 38691917)
20. Shen Y, Tong L (2008) Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1. Biochemistry 47:5767-5773. (Pubitemid 351747055)
21. Campbell SJ, Edwards RA, Glover JN (2010) Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1. Structure 18:167-176.
22. Coquelle N, Green R, Glover JN (2011) Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. Biochemistry 50:4579-4589.
23. Meza JE, Brzovic PS, King MC, Klevit RE (1999) Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1. J Biol Chem 274:5659-5665. (Pubitemid 29109218)
24. Lipkowitz S, Weissman AM (2011) RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 11:629-643.
25. Bienstock RJ, Darden T, Wiseman R, Pedersen L, Barrett JC (1996) Molecular modeling of the amino-terminal zinc ring domain of BRCA1. Cancer Res 56:2539-2545. (Pubitemid 26170691)
26. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, et al. (1999) RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 96:11364-11369. (Pubitemid 29487386)
27. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, et al. (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430-440. (Pubitemid 26414587)
28. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, et al. (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276:14537-14540.
29. Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D, 3rd, et al. (2003) Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci U S A 100:5646-5651. (Pubitemid 36576862)
30. Greenberg RA Cancer. BRCAI, everything but the RING? Science 334:459-460.
31. Porollo A, Meller J (2007) Versatile annotation and publication quality visualization of protein complexes using POLYVIEW-3D. BMC Bioinformatics 8:316.
32. Rodriguez JA, Henderson BR (2000) Identification of a functional nuclear export sequence in BRCA1. J Biol Chem 275:38589-38596. (Pubitemid 32009187)
33. Henderson BR (2005) Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking. Bioessays 27:884-893. (Pubitemid 41415943)
34. Ye Y, Rape M (2009) Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol 10:755-764.
35. Christensen DE, Brzovic PS, Klevit RE (2007) E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. Nat Struct Mol Biol 14:941-948. (Pubitemid 47525175)
36. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, et al. (2011) BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 477:179-184.
37. You Z, Bailis JM (2010) DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. Trends Cell Biol 20:402-409.
38. Calvo V, Beato M (2011) BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res 71:3422-3431.
39. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, et al. (2010) BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol 24:76-90.
40. Heine GF, Parvin JD (2007) BRCA1 control of steroid receptor ubiquitination. Sci STKE 2007:pe34.
41. Brzovic PS, Meza JE, King MC, Klevit RE (2001) BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J Biol Chem 276:41399-41406.
42. Atipairin A, Canyuk B, Ratanaphan A (2011) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Res Treat 126:203-209.
43. Atipairin A, Canyuk B, Ratanaphan A (2010) Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability. Chem Biodivers 7:1949-1967.
44. Deng CX, Brodie SG (2000) Roles of BRCA1 and its interacting proteins. Bioessays 22:728-737. (Pubitemid 30613304)
45. Classon M, Harlow E (2002) The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910-917. (Pubitemid 37328892)
46. Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, et al. (1999) BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci USA 96:11866-11871. (Pubitemid 29502824)
47. Zhong Q, Chen CF, Li S, Chen Y, Wang CC, et al. (1999) Association of BRCA1 with the hRad50-hMrell-p95 complex and the DNA damage response. Science 285:747-750.
48. Scully R, Chen J, Plug A, Xiao Y, Weaver D, et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88:265-275. (Pubitemid 28015875)
49. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, et al. (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 103:17834-17839. (Pubitemid 44852246)
50. Wang Q, Zhang H, Kajino K, Greene MI (1998) BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17:1939-1948. (Pubitemid 28488462)
51. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, et al. (1996) The nuclear localization sequences of the BRCA1 protein interact with the importinalpha subunit of the nuclear transport signal receptor. J Biol Chem 271:32863-32868. (Pubitemid 27008717)
52. Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 106:7155-7160.
53. Traven A, Heierhorst J (2005) SQ/TQ cluster domains: concentrated ATM/ATR kinase phosphorylation site regions in DNA-damage-response proteins. Bioessays 27:397-407. (Pubitemid 40592596)
54. Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to double-strand breaks. Science 286:1162-1166.
55. Leung CC, Glover JN (2011) BRCT domains: easy as one, two, three. Cell Cycle 10:2461-2470.
56. Mohammad DH, Yaffe MB (2009) 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair (Amst) 8:1009-1017.
57. Yu X, Chini CC, He M, Mer G, Chen J (2003) The BRCT domain is a phospho-protein binding domain. Science 302:639-642. (Pubitemid 37310919)
58. Yu X, Chen J (2004) DNA damage-induced cell cycle checkpoint control requires CtIP, a phosplrorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 24:9478-9486. (Pubitemid 39391684)
59. Kim H, Huang J, Chen J (2007) CCDC98 is a BRCA1-BRCT domainbinding protein involved in the DNA damage response. Nat Struct Mol Biol 14:710-715. (Pubitemid 47220062)
60. Yamane K, Katayama E, Tsuruo T (2000) The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature. Biochem Biophys Res Commun 279:678-684. (Pubitemid 32016774)
61. Kobayashi M, Ab E, Bonvin AM, Siegal G (2010) Structure of the DNA-bound BRCA1 C-terminal region from human replication factor C pl40 and model of the protein-DNA complex. J Biol Chem 285:10087-10097.
62. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38, 27-38. (Pubitemid 26152973)
63. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, et al. (1994) Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 8:387-391. (Pubitemid 24375606)
64. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122. (Pubitemid 24345332)
65. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71. (Pubitemid 24345325)
66. Liu J, Pan Y, Ma B, Nussinov R (2006) "Similarity trap" in protein-protein interactions could be carcinogenic: simulations of p53 core domain complexed with 53BP1 and BRCA1 BRCT domains. Structure 14:1811-1821. (Pubitemid 44855629)
67. Gough CA, Gojobori T, Imanishi T (2007) Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study. Proteins 66:69-86. (Pubitemid 44955980)
68. Javle M, Curtin NJ The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105:1114-1122.
69. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, et al. (2011) BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20:797-809.
70. Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, et al. (2009) Cdkl participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell 35:327-339.
71. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, et al. (2011) Compromised CDK1 activity sensitizes BRCA-proflcient cancers to PARP inhibition. Nat Med 17:875-882.